Smith & Nephew (LON:SN) Stock Price Crosses Above 200 Day Moving Average – Should You Sell?

Smith & Nephew plc (LON:SN) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 1,297.06 and traded as high as GBX 1,307. Smith & Nephew shares last traded at GBX 1,306.50, with a volume of 2,454,084 shares trading hands.

Analyst Upgrades and Downgrades

Several analysts have recently commented on SN shares. Citigroup increased their price objective on Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the stock a “buy” rating in a research note on Friday, October 31st. Royal Bank Of Canada lowered Smith & Nephew to a “sector perform” rating and lowered their price target for the company from GBX 1,700 to GBX 1,350 in a research report on Wednesday, December 17th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Smith & Nephew in a report on Friday, November 7th. Berenberg Bank reiterated a “hold” rating and issued a GBX 1,300 target price on shares of Smith & Nephew in a research note on Friday, January 23rd. Finally, Panmure Gordon reissued a “hold” rating and set a GBX 1,200 price target on shares of Smith & Nephew in a research report on Tuesday, December 9th. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of GBX 1,381.33.

Smith & Nephew Trading Up 1.4%

The stock’s 50 day simple moving average is GBX 1,239.21 and its two-hundred day simple moving average is GBX 1,297.06. The stock has a market capitalization of £14.53 billion, a PE ratio of 47.70, a PEG ratio of 0.46 and a beta of 0.62. The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.